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ARTICLE OPEN
Prophylactic effects of isomaltodextrin in a Balb/c mouse
model of egg allergy
Yoshinori Mine1*, Yan Jin1,3, Hua Zhang1, Prithy Rupa1, Kaustav Majumder1,4, Takeo Sakurai2, Yoshifumi Taniguchi2, Ryodai Takagaki2,
Hikaru Watanabe2 and Hitoshi Mitsuzumi2
The aim of this study was to evaluate the potential effects of isomaltodextrin (IMD), a dietary saccharide polymer derived from
enzymatically produced from starch, on the ability to alter immune response (IR) bias to hen egg ovalbumin (Ova) induced allergic
inflammation in mice. Groups of Balb/c mice were pre-treated with various doses of IMD in drinking water (1.0, 2.5, and 5.0% w/v)
for 6 weeks and subsequently sensitized to the Ova together with continuous administration of IMD. To evaluate changes in
immune response bias, immunoglobulin isotype-associated antibody activity, concentrations of type 1 and 2 cytokines and the
percentage of T-regulatory cells (T-regs) in blood were measured. Clinical signs of allergy were assessed after oral challenge with
Ova. Treatment with IMD did not significantly alter the frequency of clinical signs, however there was a trend in the overall
reduction of clinical signs. Effect on IR bias was observed in the treatment groups as reflected by reduction in a type 1-biased
phenotype as evident by decrease in isotype-specific IgE, IgG and increase in IL-12 cytokine production and a high proportion of T-
regs. This study revealed that IMD could be a useful prophylactic candidate for alteration of allergic IR bias in mice and an immune-
stimulator for reducing egg induced allergic reactions.
npj Science of Food            (2019) 3:23 ; https://doi.org/10.1038/s41538-019-0057-5
INTRODUCTION
Foods that may cause allergic reactions are particularly insidious.
Food allergy, an adverse immunologic reaction to food, affects
6–8% of children and 4% of adults in North America.1,2 The
prevalence of food allergy in children (aged 0 to 17 years) has
slowly increased in the USA, from 3.4% in 1997–1999 to 5.1% in
2009–2011, associated the major foods of milk, eggs, fish,
crustacean shellfish, wheat, soy, peanuts, and tree nuts.3 It has
been reported that 7.5% of Canadians—7.7% of adults and 6.9%
of children under 18 years of age having at least one food allergy,
most commonly associated with peanut, tree nut, fish, shellfish,
sesame, milk, egg, wheat, and soy.4 Both the prevalence and
severity of food allergies have increased in past few decades.5,6
Egg, milk, and peanut together contribute to nearly 90% of the
food allergies.7 A recent study by FAAN (Food Allergy and
Anaphylaxis Network) and FARP (Food Allergy Research and
Resource Program) reported that over 12 million Americans suffer
from food allergies.8,9 This indicates that food allergies are
occurring at an alarmingly high rate, pressing the need for
efficient preventive measures. The prevalence of childhood food
allergy and the duration of these allergies, particularly those
considered to be transient, like egg and milk allergy continues to
increase. Methods to evaluate the potential allergenicity of foods
are limited and research in developing assessment tools is needed
to investigate factors for allergenic susceptibility and to improve
on valid animal models for food allergy. Food allergies not only
affect the susceptible individuals but also have an impact on food
industries especially with the labeling laws and manufacturing
practices.
To reduce the risk of food allergy, anti-IgE therapy, SOTI (specific
oral tolerance induction), PIT (peptide-based immunotherapy),
DNA-based immunotherapy, genetically engineered egg allergens
and off late probiotics have come up with promising results but
needs an in-depth study.10 Also, currently available therapeutics
(anti-histamine, epinephrine, and steroids) provide only sympto-
matic relief. Due to the complex nature of allergic disease,
standard treatments are limited to allergen avoidance, nutritional
support, and immediate access to emergency medication.
Immunoglobulin E (IgE)-mediated immune response to egg
proteins in food can be life-threatening, leading to responses
ranging from repeated scratching, diarrhea, vomiting, and rarely
resulting in death.11 Mainly glycoproteins from egg white have
been identified as food allergens. Among all the glycoproteins,
egg white Ovalbumin (Ova), and ovomucoid (Ovm) are classified
as dominant allergens and play a crucial role in the egg-induced
allergenic response.12 Ovm is heat resistant and resistant to
digestive enzymes whereas Ova is easily digested and absorbed in
the gut.13
Most individuals who suffer from food allergy are polysensitized
and therefore allergic to more than one food.14 Allergen specific
immunotherapies would not be beneficial in this case and hence
the use of allergen-nonspecific therapy could circumvent this
problem by enabling change in the host immune response (IR),
which ideally would induce tolerance toward all food allergens.
Polysaccharides have been shown to act as prebiotics with IR
modulating properties for the prevention of food allergies.15
Prebiotics are defined as “a substrate that is selectively utilized
by host microorganisms conferring a health benefit”.16 The criteria
that are classically met by dietary prebiotics are: resistance to
acidic gastric pH and mammalian digestive enzymes, as well as
high absorption yield through the gastrointestinal (GI) tract.
Maltodextrins are branched polysaccharides composed by a
maximum of seventeen chains of dextrose molecules, linked with
alpha-glycosidic bonds consisting of α (1→ 4) and α (1→ 6) linked
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D-glucose units. Isomaltodextrin (IMD) (GI resistant maltodextrin)
is a highly branched soluble α-glucan with a relatively low degree
of polymerization.17 This glucan partially escapes digestion in the
small intestine and may undergo fermentation by bacteria in the
large intestine, and therefore, it could play a role as a
prebiotic.17,18 It is considered as generally recognized as safe
(GRAS) by the US Food and Drug Administration (FDA).
Fructooligosaccharides (FOSs) occur naturally in a wide variety
of foods. In fact, Americans consume ~2.5 g of inulin and
oligofructose daily (range of 1–4 g), mostly from wheat and
onions.19 In terms of safety, FOSs cause few adverse effects, and
the adverse effects are minor in nature.20
Maltodextrin and its enzymatically modified forms have been
investigated for different biomedical properties. IMD was digested
partially only by small intestinal mucosal membrane in healthy
subjects and reduced the glucose.21,22 The efficacy of IMD in the
treatment of intestinal inflammation was also investigated in a
mouse model of colitis and resulted in a significant reduction in
the expression of pro-inflammatory mediators TNF-α and IL-8, as
well as pattern recognition receptor TLR4.23 However, the effect of
IMD on allergenic response has not been elucidated yet. There-
fore, the primary objective of the current project is to evaluate the
effect of IMD on Ova-induced allergenic response in mice. It was
hypothesized that IMD could alter the IR phenotype and
expression of allergy in mice sensitized to the egg white
allergen Ova.
RESULTS
Clinical scores and allergenic response of mice
On the final experimental day, allergic reaction was induced into
the mice by oral gavage by 20mg of Ova and then the mice were
observed for next 30min for clinical scoring. Figure 1 illustrated
the clinical signs observed in different groups of mice. Clinical
scores were assigned and the total scores for each animal were
obtained by adding scores for the individual symptoms of
scratching, sneezing, isolation, diarrhea and lethargy and respira-
tory difficulty. Post challenge, animals in the positive control
group developed statistically significant clinical scores (3.889 ±
0.254) of allergies as compared to the negative control (1.182 ±
0.296) (p < 0.0001). Prevention groups with IMD (Low-L, Medium-
M, and High-H) (L: 3.500 ± 0.267, M: 3.200 ± 0.291, H: 3.417 ± 0.288)
did not reach any statistical significance compared to the positive
control group, however a trend towards a decrease in clinical
scores was observed with the treatment groups compared to the
positive control.
Histamine and mast cell protease concentration
Histamine and mast cell protease concentration were evaluated as
a measure for the mast cell activation and degranulation. Both
histamine and mast cell protease concentration were increased in
the positive control (Histamines: 70.598 ± 7.043 ng/mL, MMCPT-1:
1354.313 ± 196.402 ng/mL) significantly compared to the negative
control group (Histamine: 22.957 ± 2.053 ng/mL, P < 0.0001,
MMCPT-1: 312.712 ± 35.882 ng/mL, P < 0.001). Prevention groups
of low, medium, and high-dose IMD showed statistical significant
decrease in histamine (L: 31.835 ± 4.957 ng/mL, P < 0.001; M:
24.297 ± 5.452 ng/mL, P < 0.0001; H:23.251 ± 7.877 ng/mL, P <
0.0001) as compared to positive control group. Prevention groups
with low and high-dose IMD showed statistical significant
decrease in mast cell protease (L: 682.140 ± 56.801 ng/mL, P <
0.05; H:641.263 ± 36.807 ng/mL, P < 0.05) compared to positive
control group. Prevention group of medium-dose IMD (717.737 ±
103.845 ng/mL) did not show statistical significant decrease in
mast cell protease compared to positive control group (Fig. 2, p <
0.05). However, there was no significant difference observed with
the IMD treated groups (p > 0.05) with both histamine and mast
cell protease concentration as measured.
Antibody concentrations in plasma and feces
Specific and total antibody levels were measured in the blood
plasma. There was a significant reduction of total IgG, total IgG1,
and IgG2a in all the three prevention groups (IgG L: 478.745 ±
Fig. 1 Clinical scores for individual mice. Total clinical scores for
each mice post-Ova challenge were calculated. Average scores
assigned by four independent observers in a blinded fashion are
represented. Different letters indicate statistically significant
differences
Fig. 2 Serum histamine and mouse mast cell protease concentra-
tion. Data for serum histamine and MMCP concentration are
represented as mean ± standard deviation (n= 6 pooled sera).
Different letters indicate statistically significant differences (p <
0.05) between groups of mice
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6.409 ng/mL, P < 0.0001 M: 467.624 ± 21.669 ng/mL, P < 0.0001, H:
522.438 ± 4.696 ng/mL, P < 0.0001 vs. PC: 948.307 ± 28.469 ng/mL;
IgG1 L: 4326.344 ± 332.243 pg/mL, P < 0.001 M: 4106.144 ±
255.851 pg/mL, P < 0.0001, H: 4766.541 ± 236.048 pg/mL, P < 0.05
vs. PC: 5627.638 ± 101.712 pg/mL; IgG2a L: 105.034 ± 36.056 ng/
mL, P < 0.01, M: 88.636 ± 12.297 ng/mL, P < 0.01, H: 105.825 ±
48.216 ng/mL, P < 0.01 vs. PC: 329.994 ± 40.947 ng/mL) (Fig. 3).
The total IgE showed no statistical significant difference in
all three prevention groups (L: 27748.230 ± 3598.297 ng/mL,
M:29495.240 ± 3975.996 ng/mL, H: 26272.100 ± 3269.893 ng/mL)
compared to positive control group (31957.490 ± 5805.165 ng/
mL). Specific IgG2a was significantly reduced in the high dose IMD
group (1.741 ± 0.043) compared to positive control group (1.983 ±
0.033, P < 0.01). Specific IgG1(L: 1.324 ± 0.032, P < 0.0001, M:
1.230 ± 0.034, P < 0.0001 H:1.225 ± 0.036, P < 0.0001) and specific
IgE (L: 0.941 ± 0.121, P < 0.0001 M: 0.908 ± 0.104, P < 0.0001,
H:0.868 ± 0.095, P < 0.0001) levels decreased significantly after
IMD pre-treatment in all three doses as compared to the positive
control group (specific IgG1:1.924 ± 0.032; specific IgE: 1.504 ±
0.089) (Fig. 4). The specific IgA level was measured from the total
protein extracted from the mice feces. The specific IgA showed no
significant change in the prevention groups as compared to the
positive control group (Fig. 5).
Cytokine concentration
Cytokine expression in splenocyte was measured from the
cultured spleen cells. No statistically significant difference was
observed in the prevention groups as compared to the positive
and negative control groups with IL-4, IL-10, and IL-17
concentrations (Fig. 6) (p > 0.05). Although the clear significant
was not observed due to high variable of ranges, the trend of
decreasing IL-4, while increasing IL-10 and IL-17 was observed.
Prevention groups of medium dose (35.440 ± 3.908 pg/mL, P <
0.01) and high dose (35.475 ± 2.054 pg/mL, P < 0.05) of IMD
showed statistical significantly decreased of TGF-β as compared
to positive control group (58.957 ± 4.054 pg/mL). High-dose
prevention group (3.226 ± 1.346 ng/mL, P < 0.05) significantly
decreased IFN-γ compared to positive control group (19.546 ±
3.071 ng/mL). IL-12 concentration was significantly increased
in a dose-dependent manner after IMD treatment with the
TM (476.945 ± 119.006 pg/mL, P < 0.05) and TH (589.460 ±
90.797 pg/mL, P < 0.01) compared to PC group (13.654 ±
2.507 pg/mL) (Fig. 6).
Percentage of Treg cells
The flow cytometry analysis showed that the percentage of Foxp3
and CD25+ cells significantly increased in all the three prevention
groups (L: 51.700 ± 3.758, M: 50.717 ± 7.349, H: 49.400 ± 9.489)
(Fig. 7) as compared to those in the positive control group
(19.600 ± 5.424) (p < 0.05).
DISCUSSION
Food allergy is an immunologically adverse reaction caused by
foods. It is an IgE-dependent type I hypersensitivity reaction due
to the imbalance of Th1/Th2. A food allergic murine model
sensitized by intraperitoneally followed by the orally challenge of
anti-allergic bioactive compounds was established in our past
Fig. 3 Total IgG (whole molecule), IgE, IgG1, and IgG2 related antibody activity. Rabbit anti-mouse IgG conjugated to alkaline phosphatase
was used for detection of IgG and rat monoclonal anti-mouse IgE was used for IgE followed by streptavidin-HRP conjugate. Different letters
indicate statistically significant differences at p < 0.05
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study.24 The present data suggested that pre-treatment with IMD
(for 6 weeks) and continuous administration of IMD (week 7–11)
during Ova sensitization influence the IR bias of mice undergoing
allergic sensitization to Ova. The greatest effect was observed in
TM and TH groups, which had an anti-allergic type 1-biased
phenotype as measured by isotype-specific antibody (IgG1 and
IgE) activity, relatively increased type 1-associated cytokine
production (IL-12), as well as high proportion of circulating T-reg
cells. Given this, it was found that mice treated with TL were more
susceptible to developing clinical allergy than those treated with
TM or TH. Furthermore, TH prevention group was more protective
against allergy based on most of the biomarkers measured such as
the decrease in specific IgG response in addition to other balance
IR parameters. Thus, of all the three prevention groups, the IMD-
TH treated mice displayed an increased ability to respond to Ova
in terms of antibody activity (decreased specific IgG, IgG1, and IgE)
and had more balanced cytokine profiles than mice otherwise
treated. In order to elucidate mechanisms of anti-allergic response
of IMD, we focused on Foxp3+ Treg (CD4+ CD25+ Foxp3+ T)
cells. The expression of Foxp3 in mouse treated with TM and TH
was increased in mice, suggesting that Treg cell polarization was
promoted by IMD.
Oral immunotherapy (OIT) is a promising therapeutic approach
to treat food allergic patients, however, it is generally considered
as medication. Nutritional interventions may provide a new insight
to improve the efficacy of OIT for food allergic patients. Dietary
non-digestible oligosaccharides mimic the immunomodulatory
effects exerted by human milk oligosaccharides in breast-fed
infants and have been shown to reduce the risk of developing
allergic diseases.25 It is also reported that digestible oligosacchar-
ides can cross the intestinal epithelial barrier and directly affect
immune cells involved in the process of oral tolerance induc-
tion.26,27 The capacity of non-digestible oligosaccharides to induce
IR modulation and suppress allergic reactions in murine food
allergy models suggests they may provide a potential benefit in
combination with OIT strategies.28,29 It has been reported that
oligosaccharide prebiotics have been shown to have a protective
effect against allergic manifestations in high risk infants.30 Earlier
studies have also described that IMD was digested partially only
by small intestinal mucosal enzymes, and maltase and isomaltose
activities were weakly inhibited.22 In this study the effect of IMD
could only partially reduce clinical allergic signs, however there
Fig. 4 Ova-specific serum IgG, IgG1, IgG2, and IgE-related antibody activity. Rat monoclonal anti-mouse, IgG, IgG1, IgG2a, and IgE were used
followed by streptavidin-HRP conjugate. Different letters indicate statistically significant differences at p < 0.05
Fig. 5 Ova-specific IgA was detected from pooled fecal samples
collected from weeks 9–11 using biotinylated rat monoclonal anti-
mouse IgA antibody followed by avidin-HRP conjugate. Different
letters indicate statistically significant differences
Y. Mine et al.
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was a skewed immune response from a type 2 allergic response to
a type 1 pro-inflammatory response by the TH group. These
effects could be attributed to the dosage and to the digestibility of
IMD by the intestinal mucosal enzymes.
Also, IMD has been confirmed to stabilize micron sized micelles
in a manner similar to that of resistant maltodextrin, suggesting
the inhibitory effects of IMD on the progression of micronization
of micelles.31 Adhesion of IMD on the particle surface may have
caused an increase in the surface potential.32 This could also be
attributed to the mechanism of inhibition of allergic response in
this study that may have been based on the increase on the
surface potential and the dose of IMD used. Thus, it could be
concluded that mice treated with TL and TM were comparatively
more susceptible to developing clinical allergy than those treated
with TH group which was inclined towards protecting against
allergy. Hence in this study, the high dosage of IMD could be a
major factor in influencing the suppression of allergic IR. The
activity of IMD could also be related to the extent and mechanism
of its degradation in the gut that may have influenced the
suppression of the allergic response. Also, IMD is resistant to
enzymatic hydrolysis, allowing it to pass into the large intestine.
Prebiotic stimulates the growth of protective commensal
microbes in the gut significantly changed in infancy fecal
microbiota which are associated with the development of food
allergy.33 The proportion of abundant Bacteroidetes, Proteobac-
teria, and Actinobacteria phyla were significantly reduced, while
the Firmicutes phylum was highly enriched in the food allergy
group.34,35 A growing body of evidence suggests that gut
microbiota plays an essential role in gut health and promoting
local and systemic immunity. In food allergy children compare to
healthy subjects, different levels of short chain fatty acids (SCFAs),
in particular of butyrate, have been described.36,37 Thus, it is also
necessary studying the effect of IMD on microbiota change, SCFAs
or of other microbiota-derived metabolites production that could
prevent food allergy and modulate immune system in future work.
It is well known that IMD is water soluble and directly extracted
from plants or made from starch and is generally regarded as
safe.27 Hence using IMD as a prophylactic candidate for curing egg
allergy is a promising approach.
In conclusion, these data provide evidence for the role of IMD in
prevention of OVA allergic response in mice by inducing immune
tolerance through several ways that includes a Th2-skewed to a
Th1-skewed response, a regulatory response involving the
transcription factor Foxp3, induction of an increase IL-12 response,
and influencing mast cell functionality (suppression of histamine
and MMCPT-1). This may suggest that IMD could be a potentially
useful candidate for the design of a functional prebiotic food
component in targeting management of food allergy.
METHODS
Experimental design-mice and sensitization
A total of 60 mice (12 per group) were used. The mice were housed and
maintained under normal husbandry conditions at the Central Animal
Facility (University of Guelph). All experimental protocols were in
accordance with the Canadian Council for Animal Care guidelines and all
animal use protocols were approved by University of Guelph Animal Care
Committee (AUP 1567).
Pre-treatments and sensitization
Figure 8 summarizes the pre-treatment, sensitization, sampling, and
challenge schedule. Groups of mice (12 per group) were assigned to
one of three prevention groups (IMD in drinking water (1.0, 2.5%,
and 5.0% w/v) were administered ad lib for 6 weeks) prior to
sensitization and continued during sensitization period. Group A
was treated with phosphate-buffered saline (PBS; negative
control). Ovalbumin (Ova: 50 μg/mice) was given by intraperito-
neal injection (IP) (dissolved in 50 μL of saline and 50 μL of
aluminum hydroxide gel adjuvant; Sigma-Aldrich, St Louis, MO) at
weeks 7, 8, and 9. Blood was taken on week 12 to measure specific
IgE as an indication of allergic sensitization and confirmed its
sensitization (data not shown). Mice were allowed to fast
overnight for 8 h prior to oral challenge on week 13 with 20mg
of Ova given orally via gavage. All mice were humanely
euthanized after 30 min of monitoring for allergic signs. Blood
was collected for various biomarker assays such as measurement
of histamine, mast cell protease, antibody activity and flow
cytometry analysis. Spleen was collected for measuring cytokines.
Fig. 6 Cytokine concentration. Spleen was collected from each mouse and pooled within groups (n= 6) and splenocytes were isolated and
cultured at 2.5 × 106 cells/mL concentration of cells in triplicate wells as unstimulated (control) or stimulated with 50 μg/well of Ova for 72 h.
The cytokine concentration of cell culture supernatants for IL-4, IFN-γ, IL-12, IL-10, TGF-β, and IL-17 were determined by ELISA. Different letters
indicate significant difference between groups for each cytokine. Significance was taken at p ≤ 0.05
Y. Mine et al.
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Clinical signs
Allergic clinical signs were evaluated in a blinded fashion by four
experienced independent observers and scores were assigned as
described earlier.24 In order to be classified as allergic, mice had to exhibit
clinical signs such as scratching, lethargy, gastrointestinal signs (diarrhea
and bloody stool) and respiratory difficulty had to occur in combination
with one of the aforementioned signs to be scored as a sign and were not
themselves sufficient to identify a mouse as allergic. Thus, signs were
additive, and clinical score was indicative of the severity of the allergic
reaction.
Histamine and mouse mast cell protease assay
Histamine concentrations in serum were determined by Enzyme-Linked
Immunosorbent Assay (ELISA) using a commercial kit (Histamine EIA, LDN
Labor Diagnostika Nord, Nordhon, Germany) as described by the
manufacturer. The mouse mast cell protease enzyme (MMCP) concentra-
tion was quantified by ELISA as per manufacturer’s recommendation
(eBiosciences, California, USA).
Measurement of immunoglobulin isotype-specific antibody
activity to Ova by enzyme-linked immunosorbent assay
Sera obtained on week 13 and stored at −80 °C were used to determine
the Ig isotype-specific antibody activity to Ova by enzyme-linked
immunosorbent assay (ELISA). Determination of individual subclasses
of serum allergen-specific IgE, IgG, IgG1, IgG2a, and feces sp-IgA were
examined. Optimal antigen-coating conditions were determined. Briefly,
96-well microtiter plates (Costar, Corning Inc., NY, USA) were coated with
2 µg/well of Ova (in 100 µL of 50 mM carbonate buffer; NaHCO3/Na2CO3,
pH 9.6) for 24 h at 4 °C. Rabbit anti-mouse IgE conjugated to alkaline
phosphatase was used for the detection of IgE, and rat monoclonal anti-
mouse IgA was used for IgA followed by streptavidin–HRP conjugate. For
Fig. 7 Flow cytometry. A representative image of CD25+ Foxp3+ cells for each group is shown. Percentage of CD25 + Foxp3+ cells were
determined by FACS from whole blood of mice collected at the end of the experiment. Different letters indicate statistically significant
differences between groups at p < 0.05
Fig. 8 Pre-treatment and sensitization protocol. Five groups of mice,
each group containing of 12 mice were used in this study. Three
groups of mice were pre-treated with three different doses of IMD
(1%, 2.5%, and 5%) given orally gavage for the first 6 weeks and
continuously administered during sensitization (week 7–11). The
negative and positive control group received just water. Mice were
sensitized with 50 µg of ovalbumin (Ova) given intraperitoneally
three times (i.p.). Negative control group did not receive any
injection. On week 13 all mice were fasted overnight and challenged
with 20mg Ova and observed for at least 30min for clinical signs of
allergy and assigned clinical scores. Blood was taken to measure
immunoglobulin isotype-associated antibody activity by enzyme-
linked immunosorbent assay (ELISA) and to isolate blood mono-
nuclear cells for culture and quantification of cytokine concentra-
tions and to measure the proportion of circulating T-regulatory cells
(T-regs) by flow cytometry
Y. Mine et al.
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IgG1 and IgG2a rat monoclonal anti-mouse IgG1 and IgG2a were used
followed by streptavidin–HRP conjugate. Plates were washed 3 times
with 200 μL of 0.05% Tween PBS (PBST 0.01 M, pH 7.4) per well) after
coating with 2% bovine serum albumin (BSA)/phosphate buffered saline
(PBS) at 37 °C for 1 h. Washing was repeated and sera diluted (1:10, 1:500
for IgE and IgG measurements, 1:100 for IgG1 and IgG2a, no dilution of
IgA) in 0.05% PBST were added at 100 μL per well and incubated for
overnight at room temperature with gentle shaking. For IgA, proteins
were extracted using appropriate inhibitor cocktail (1 mM phenylmetha-
nesulfonyl fluoride (PMSF), 0.1 mM ethylenediaminetetraacetic acid
(EDTA), 10 µg/mL aprotinin, 10 µg/mL leupeptin and 10 µg/mL pepstatin
A; Sigma-Aldrich, St Louis, MO) from feces and protein concentrations
were measured according to bicinchonimic assay (BCA) assay. Plates
were washed again and the bound antibodies were detected by adding
respective detection antibodies at room temperature for 1 h. Specific
binding activity was detected by addition of 100 µL/well of 3, 3’5, 5’-
tetramethylbenzidine substrate (Sigma-Aldrich). The reaction was
terminated with 1 N H2S04 after 30 min and absorbance at 450 nm was
measured by a micro titer reader (Bio-Rad 550, Hercules, USA). For total
antibody similar sandwich ELISA method was used but the plates were
coated by the capture antibody for each isotype.
Cytokine analysis from mouse spleen
Individual spleens were collected at the end point post challenge
aseptically from each mouse single cell suspensions were prepared.
Splenocyte cell viability was assessed by trypan blue exclusion.38 Cells
were cultured in 24 well plates in triplicate at a density of 2.5 × 106 cells/mL
as unstimulated (control) or stimulated with 50 μg/well of Ova. Culture
supernatants were collected after 72 h incubation at 37 °C and stored in
aliquots at −20 °C. Concentrations of cytokines were measured in culture
supernatants using ELISA cytokine kits following manufacturer’s instruc-
tions (ebiosciences, CA, USA for IL-4, IFN-γ, IL-10, IL-12, IL-17A, and TGF-β).
Determination of proportion of T-regulatory cells in lymphocytes
of whole blood by flow cytometry
Blood collected on week 13 was also used to measure the proportion of
blood T-regs from all mice by flow cytometry, based on CD25 and forkhead
box P3 (Foxp3) positivity. One hundred microliters of blood from each
mouse was used for double staining with anti-mouse CD25 (558642; BD
biosciences, California, USA) and R-phycoerythrin (PE)-conjugated anti-
mouse Foxp3 (eBiosciences, San Diego, CA), Analysis of labeled cells was
performed using an Accuri Flow Cytometer (BD). Isotype and unstained
controls were included to confirm specific staining of anti-CD25 and anti-
Foxp3 and to adjust compensation. The antibody isotype controls used
were mouse IgG1 negative control for CD25 and PE-conjugated rat IgG2a
for Foxp3. Unstained samples were treated with wash buffer, PBS with
0.1% bovine serum albumin (PBA). The staining protocol was used as per
the manufacturer’s instruction for whole blood sample (BD Bioscience).
Live cells were gated based on forward and 90° light scatter characteristics.
At least 10,000 events were acquired from each sample and all data sets
were analyzed using Accuri Express software (BD Bioscience).
Statistical analysis
Statistical calculations were performed using the GraphPad Prism 5.0
package (GraphPad Software, San Diego, CA, USA). All data were expressed
as means ± SEM and subjected to ANOVA analyses followed by post hoc
multiple comparison using Tukey’s test. Comparison of all the endpoint
differences with a level of P < 0.05 was considered significant.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
DATA AVAILABILITY
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